Spero Therapeutics Initiates First Clinical Study for treatment of Multidrug Resistant Gram-Negative Infections





Another promising research in battle against "Superbugs" .
As per the report from theprovince.com, Spero Therapeutics, headquartered in Cambridge, Massachusetts today announced the initiation of a Phase 1 clinical trial of SPR741, the Company's lead Potentiator molecule. The Potentiator Platform identifies novel chemical entities that disrupt the outer cell membrane of Gram-negative bacteria to permit access for a range of antimicrobial agents previously only active against Gram-positive pathogens.


Please read the full article.




http://www.theprovince.com/business/cnw/release.html?rkey=20161219C1981&filter=4007

No comments

Powered by Blogger.